The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Li, Q., Zhang, L., You, W., Xu, J., Dai, J., Hua, D., Zhang, R., Yao, F., Zhou, S., Huang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35469-x · Cited by 120
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3 β , CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability 31 – 36 .”
Xie, X., Yang, Y., Wang, Q., Liu, H.-F., Fang, X., Li, C., Jiang, Y., Wang, S., Zhao, H., Miao, J., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00766-z · Cited by 130
Shi, Q., Zhu, Y., Ma, J., Chang, K. S., Ding, D., Bai, Y., Gao, K., Zhang, P., Mo, R., Feng, K. M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1096-x · Cited by 124
Self-citationThe emerging role of SPOP protein in tumorigenesis and cancer therapy
Song, Y., Xu, Y., Pan, C., Yan, L., Wang, Z. P., & Zhu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1124-x · Cited by 126
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Suresh, S., Chen, B., Zhu, J., Golden, R. J., Lu, C., Evers, B. M., Novaresi, N., Smith, B., Zhan, X., Schmid, V., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0056-0 · Cited by 130
DAXX in cancer: phenomena, processes, mechanisms and regulation
Mahmud, I., & Liao, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz634 · Cited by 122
Adkins, D. R., Ley, J. C., Neupane, P. C., Worden, F. P., Sacco, A. G., Palka, K. A., Grilley‐Olson, J. E., Maggiore, R. J., Salama, N. N., Trinkaus, K. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30405-x · Cited by 122
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
Zhang, X., Huang, X., Xu, J., Li, E., Lao, M., Tang, T., Zhang, G., Guo, C., Zhang, X., Chen, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24769-3 · Cited by 126
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Wang, Y., Sun, Q., Mu, N., Sun, X., Wang, Y., Fan, S., Su, L., & Liu, X. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00612-y · Cited by 124
Cellular Senescence and the Immune System in Cancer
Prieto, L. I., & Baker, D. J. (2019) · Gerontology · doi:10.1159/000500683 · Cited by 124
Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.
Sun, L., Yang, R., Li, C.-W., Chen, M., Shao, B., Hsu, J.-M., Chan, L.-C., Yang, Y., Hsu, J. L., Lai, Y., et al. (2018) · Europe PMC (PubMed Central) · Cited by 118
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
Huang, J., Chen, P., Liu, K., Liu, J., Zhou, B., Wu, R., Qiu, P., Liu, Z., Li, C., Kroemer, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320441 · Cited by 123
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
Wu, Y., Zhang, C., Liu, X., He, Z., Shan, B., Zeng, Q., Zhao, Q., Zhu, H., Liao, H., Cen, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22467-8 · Cited by 117
Self-citationAPC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis
Schrock, M. S., Stromberg, B. R., Scarberry, L., & Summers, M. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.001 · Cited by 126
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Xu, Y., Song, G., Xie, S., Jiang, W., Chen, X., Chu, M., Hu, X., & Wang, Z. P. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.029 · Cited by 122
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Wu, R.-Y., Kong, P., Xia, L.-P., Huang, Y., Li, Z., Tang, Y.-Y., Chen, Y.-H., Li, X., Senthilkumar, R., Zhang, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2840 · Cited by 116
Self-citationp16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells
Majewska, J., Agrawal, A., Mayo, A., Roitman, L., Chatterjee, R., Kralova, J. S., Landsberger, T., Katzenelenbogen, Y., Meir-Salame, T., Hagai, E., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01465-0 · Cited by 126
Xiang, J., Zhang, N., Sun, H., Su, L., Zhang, C., Xu, H., Feng, J., Wang, M., Chen, J., Liu, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.10.025 · Cited by 113
Seliger, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122168 · Cited by 111
Zhou, X., Zou, L., Liao, H., Luo, J., Yang, T., Wu, J., Chen, W., Wu, K., Cen, S., Lv, D., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.016 · Cited by 112
Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116
Yang, L., Yang, Y., Zhang, J., Li, M., Yang, L., Wang, X., Chen, M., Zhang, H., He, B., Wang, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01983-1 · Cited by 131
Self-citationRegulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed Central · Cited by 108
Regulation of sister chromatid cohesion by nuclear PD-L1
Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Tu, X., Dong, H., Boughey, J. C., Goetz, M. P., Weinshilboum, R. M., Lou, Z., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0315-8 · Cited by 108
ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer
Li, K., Wu, J., Qin, B., Fan, Z.-M., Tang, Q., Lu, W., Zhang, H., Xing, F., Meng, M., Zou, S., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0257-1 · Cited by 107
Self-citationA unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
Chong, Q.-Y., Kok, Z. H., Bui, N.-L.-C., Xiang, X., Wong, A. L., Yong, W. P., Sethi, G., Lobie, P. E., Wang, L., & Goh, B.-C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104686 · Cited by 110
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 107
Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.008 · Cited by 113
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al‐Khadairi, G., & Decock, J. V. (2019) · Cancers · doi:10.3390/cancers11070984 · Cited by 104
Kok, V. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00268 · Cited by 107
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
Katoh, M. (2019) · Clinical Science · doi:10.1042/cs20180845 · Cited by 105
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 104
The diverse roles of SPOP in prostate cancer and kidney cancer
Wang, Z. P., Song, Y., Ye, M., Dai, X., Zhu, X., & Wei, W. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0314-z · Cited by 104
Self-citationMa, X., Jia, S., Wang, G., Liang, M., Guo, T., Du, H., Li, S., Li, X., Huangfu, L., Guo, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01450-3 · Cited by 107
Self-citationNF-κB and Its Role in Checkpoint Control
Betzler, A. C., Theodoraki, M., Schuler, P. J., Döscher, J., Laban, S. A., Hoffmann, T. K., & Brunner, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113949 · Cited by 106
The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage
De, S., Holvey-Bates, E. G., Mahen, K. K., Willard, B. B., & Stark, G. R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112674118 · Cited by 102
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Liu, L., Huang, X., Shi, F., Song, J., Guo, C., Yang, J., Liang, T., & Bai, X. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02273-w · Cited by 105
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 101
Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S., Ayers, G. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108944 · Cited by 109
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Self-citationFan, P., Zhao, J., Meng, Z., Wu, H., Wang, B., Wu, H., & Jin, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1044-z · Cited by 101
Li, Y., Zhang, H., Li, Q., Zou, P., Huang, X., Wu, C., & Li, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.011 · Cited by 99
Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy
Aliabadi, F., Sohrabi, B., Mostafavi, E., Pazoki–Toroudi, H., & Webster, T. J. (2021) · Open Biology · doi:10.1098/rsob.200390 · Cited by 101
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
Xu, X., Pan, X., Wang, T., Wang, J., Yang, B., He, Q., & Ding, L. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0416-4 · Cited by 103
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 102
Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J., Owonikoko, T. K., Rytlewski, J. A., Hood, J. V. W., Zhao, Y., Malik, R. K., Strum, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000847 · Cited by 100
Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity
Zhang, Z., Ren, C., Xiao, R., Ma, S., Liu, H., Dou, Y., Fan, Y., Wang, S., Zhan, P., Gao, C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adp7302 · Cited by 94
Regulatory mechanisms of PD-L1 expression in cancer cells
Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92
Engineering Precision Medicine
Sun, W., Lee, J., Zhang, S., Benyshek, C., Dokmeci, M. R., & Khademhosseini, A. (2018) · Advanced Science · doi:10.1002/advs.201801039 · Cited by 96
Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways
Liu, J., Cheng, Y., Zheng, M., Yuan, B., Wang, Z., Li, X., Yin, J., Ye, M., & Song, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00418-x · Cited by 94
The tumor microenvironment and immune responses in prostate cancer patients
Kwon, J., Bryant, R. J., & Parkes, E. E. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0149 · Cited by 93
Hashemi, M. M., Karami, S., Sarabandi, S., Moazeni‐Roodi, A., Małecki, A., Ghavami, S., & Wiecheć, E. (2019) · Cancers · doi:10.3390/cancers11081150 · Cited by 88
AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness
Wang, X., Jin, J., Wan, F., Zhao, L., Chu, H., Chen, C., Liao, G., Liu, J., Yu, Y., Teng, H., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.11.033 · Cited by 87
Hu, Y., Manasrah, B. K., McGregor, S. M., Lera, R. F., Norman, R. X., Tucker, J. B., Scribano, C. M., Yan, R. E., Humayun, M., Wisinski, K. B., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0195 · Cited by 89
CDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 84
PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity
Liu, J., Bu, X., Chu, C., Dai, X., Asara, J. M., Siciński, P., Freeman, G. J., & Wei, W. (2023) · Nature Communications · doi:10.1038/s41467-023-38443-3 · Cited by 89
Self-citationThe immunomodulatory effects of endocrine therapy in breast cancer
Huang, H., Zhou, J., Chen, H., Li, J., Zhang, C., Jiang, X., & Ni, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01788-4 · Cited by 87
Targeting ubiquitin signaling for cancer immunotherapy
Zhou, X., & Sun, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00421-2 · Cited by 87
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., Signoretti, S., Harris, I. S., Endress, J. E., & Kaelin, W. G. (2019) · Science Signaling · doi:10.1126/scisignal.aay0482 · Cited by 86
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression
Zhou, X. A., Zhou, J., Zhao, L., Yu, G., Zhan, J., Shi, C., Yuan, R., Wang, Y., Chen, C., Zhang, W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004570117 · Cited by 82
EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway
Chen, H.-N., Liang, K.-H., Lai, J.-K., Lan, C.-H., Liao, M., Hung, S.-H., Chuang, Y., Chen, K.-C., Tsuei, W. W.-F., & Wu, H. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1264 · Cited by 81
PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain
Wen, M., Cao, Y., Wu, B., Xiao, T., Cao, R., Wang, Q., Liu, X., Xue, H., Yu, Y., Lin, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25416-7 · Cited by 81
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02084-5 · Cited by 81
Self-citationPhosphorylation regulates cullin-based ubiquitination in tumorigenesis
Chen, Y., Shao, X., Cao, J., Zhu, H., Yang, B., He, Q., & Ying, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.007 · Cited by 80
Zhang, J., Zhang, G., Zhang, W., Bai, L., Wang, L., Li, T., Yan, L., Xu, Y. Y., Chen, D., Gao, W., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01012-0 · Cited by 84
Self-citationPredictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 78
Ma, G., Liang, Y., Chen, Y., Wang, L., Li, D., Liang, Z., Wang, X., Tian, D., Yang, X., & Niu, H. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0517 · Cited by 82
Zhou, B., Guo, L., Zhang, B., Liu, S., Zhang, K., Yan, J., Zhang, W., Yu, M., Chen, Z., Xu, Y., et al. (2019) · PubMed Central · Cited by 77
Dai, X., Gao, Y., & Wei, W. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.002 · Cited by 82
Self-citationChen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 84
Self-citationCanagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
Ding, L., Chen, X., Zhang, W., Dai, X., Guo, H., Pan, X., Xu, Y., Feng, J., Yuan, M., Gao, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci154754 · Cited by 84
Self-citationImmune response drives outcomes in prostate cancer: implications for immunotherapy
Meng, J., Zhou, Y., Lu, X., Bian, Z., Chen, Y., Fan, S., Zhou, J., Zhang, L., 郝宗耀, Zhang, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12887 · Cited by 77
USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1
Pan, J., Qiao, Y., Chen, C., Zang, H., Zhang, X., Qi, F., Chang, C., Yang, F., Sun, M., Lin, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04356-6 · Cited by 77
Ubiquitin ligases in cancer: Functions and clinical potentials
Duan, S., & Pagano, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.008 · Cited by 77
Zhang, W., Shi, L., Zhao, Z., Du, P., Ye, X., Li, D., Cai, Z., Han, J., & Cai, J. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03800-x · Cited by 76
USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1
Kuang, Z., Liu, X., Zhang, N., Dong, J., Sun, C., Yin, M., Wang, Y., Liu, L., Xiao, D., Zhou, X., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01219-9 · Cited by 82
The ubiquitin ligase adaptor SPOP in cancer
Cuneo, M. J., & Mittag, T. (2019) · FEBS Journal · doi:10.1111/febs.15056 · Cited by 79
Xu, K., Ma, J., Hall, S. R. R., Peng, R., Yang, H., & Yao, F. (2023) · Theranostics · doi:10.7150/thno.80184 · Cited by 77
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 88
CD4 + T cells aggravate hemorrhagic brain injury
Shi, S. X.-Y., Xiu, Y., Li, Y., Yuan, M., Shi, K., Liu, Q., Wang, X., & Jin, W.-N. (2023) · Science Advances · doi:10.1126/sciadv.abq0712 · Cited by 77
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
Garutti, M., Targato, G., Buriolla, S., Palmero, L., Minisini, A. M., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10061334 · Cited by 75
The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Lin, J., Guo, D., Liu, H., Zhou, W., Wang, C., Müller, I. I., Kossenkov, A. V., Drapkin, R., Bitler, B. G., Helin, K., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0754 · Cited by 74
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 73
UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity
He, C., Xing, X., Chen, H.-Y., Gao, M., Shi, J., Xiang, B., Xiao, X., Sun, Y., Yu, H., Xu, G., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.01.024 · Cited by 75
Self-citationTang, X., Sheng, Q., Xu, C., Li, M., Rao, J., Wang, X., Long, Y., Tao, Y., He, X., Zhang, Z., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101083 · Cited by 73
Kornepati, A. V. R., Boyd, J. T., Murray, C. E., Saifetiarova, J., Avalos, B. D. L. P., Rogers, C. M., Bai, H., Padron, A. S., Liao, Y., Ontiveros, C. O., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2076 · Cited by 73
Immunomodulatory Roles of Cell Cycle Regulators
Laphanuwat, P., & Jirawatnotai, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00023 · Cited by 71
The Renaissance of Cyclin Dependent Kinase Inhibitors
Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 71
Pan, C., Yang, H., Lu, Y., Hu, S., Wu, Y., He, Q., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113170 · Cited by 72
Zhang, H., Xia, Y., Wang, F., Luo, M., Yang, K., Liang, S., An, S., Wu, S., Yang, C., Chen, D., et al. (2021) · Advanced Science · doi:10.1002/advs.202003404 · Cited by 69
Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1
Ren, W., Xu, Z., Chang, Y., Ju, F., Wu, H., Liang, Z., Zhao, M., Wang, N., Lin, Y., Xu, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44466-7 · Cited by 68
Self-citationQuantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
Nimmagadda, S. (2020) · Cancers · doi:10.3390/cancers12113173 · Cited by 68
Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy
Fontana, F., Anselmi, M., & Limonta, P. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215619 · Cited by 68
S6K1-mediated phosphorylation of PDK1 impairs AKT kinase activity and oncogenic functions
Jiang, Q., Zhang, X., Dai, X., Han, S., Wu, X., Wang, L., Wei, W., Zhang, N., Xie, W., & Guo, J. (2022) · Nature Communications · doi:10.1038/s41467-022-28910-8 · Cited by 68
Self-citationRegulation of PD-L1 through direct binding of cholesterol to CRAC motifs
Wang, Q., Cao, Y., Shen, L., Xiao, T., Cao, R., Wei, S., Tang, M., Du, L., Wu, H., Wu, B., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq4722 · Cited by 66
Liu, J., Wei, L., Hu, N., Wang, D., Ni, J., Zhang, S., Liu, H., Lv, T., Yin, J., Ye, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005116 · Cited by 68
Yin, M., Dong, J., Sun, C., Liu, X., Liu, Z., Liu, L., Kuang, Z., Zhang, N., Xiao, D., Zhou, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202206737 · Cited by 70
Wang, Q., Wang, J., Yu, D., Zhang, Q., Hu, H., Xu, M., Zhang, H., Tian, S., Zheng, G., Lu, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101357 · Cited by 67
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Huang, C., Ren, S., Chen, Y., Liu, A., Wu, Q., Jiang, T., Lv, P., Song, D., Hu, F., Lan, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4186 · Cited by 67
Self-citationLelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
